Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDRX Biodexa Pharmaceuticals	$0.84 -4.5%	$1.07	$0.78 ▼ $25.50	$32.16M	1.17	1.18 million shs	785,221 shs
ESLA Estrella Immunopharma	$0.84 -0.7%	$0.96	$0.63 ▼ $3.23	$30.77M	0.36	125,337 shs	14,720 shs
GOVX GeoVax Labs	$0.73 +6.4%	$0.91	$0.43 ▼ $11.18	$10.99M	3.36	3.14 million shs	2.53 million shs
SNYR Synergy CHC	$3.43 +0.9%	$2.41	$0.36 ▼ $10.00	$31.26M	N/A	91,457 shs	61,772 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDRX Biodexa Pharmaceuticals	-10.21%	+1.02%	-17.77%	-39.73%	+87,989,900.00%
ESLA Estrella Immunopharma	-5.54%	-4.06%	-12.92%	-0.05%	-44.27%
GOVX GeoVax Labs	+0.73%	+6.50%	-33.00%	-23.53%	-75.44%
SNYR Synergy CHC	+0.29%	+3.03%	+63.46%	+36.00%	+1,689.47%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BDRX Biodexa Pharmaceuticals	0.2328 of 5 stars	0.0	3.0	2.2	0.0	0.0
ESLA Estrella Immunopharma	3.1268 of 5 stars	3.5	5.0	3.3	1.7	0.0
GOVX GeoVax Labs	2.2187 of 5 stars	3.6	2.0	3.3	0.0	0.6
SNYR Synergy CHC	3.9137 of 5 stars	3.8	0.0	3.3	3.3	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDRX Biodexa Pharmaceuticals	0.00	N/A	N/A	N/A
ESLA Estrella Immunopharma	3.00	Buy	$16.00	1,793.94% Upside
GOVX GeoVax Labs	3.20	Buy	$8.88	1,108.30% Upside
SNYR Synergy CHC	3.50	Strong Buy	$10.00	191.55% Upside

Current Analyst Ratings Breakdown

Latest GOVX, ESLA, BDRX, and SNYR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
5/29/2025	ESLA Estrella Immunopharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/2/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $9.00
4/16/2025	GOVX GeoVax Labs	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDRX Biodexa Pharmaceuticals	N/A	N/A	N/A	N/A	$0.29 per share	N/A
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	$0.12 per share	N/A
GOVX GeoVax Labs	$3.95M	2.96	N/A	N/A	$0.48 per share	1.53
SNYR Synergy CHC	$34.83M	0.91	$0.27 per share	12.78	($1.91) per share	-1.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDRX Biodexa Pharmaceuticals	-$7.32M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
ESLA Estrella Immunopharma	-$7.31M	-$0.26	N/A	∞	N/A	N/A	-1,132.38%	-273.91%	N/A
GOVX GeoVax Labs	-$24.99M	-$3.65	N/A	N/A	N/A	-438.20%	-511.96%	-286.58%	8/5/2025 (Estimated)
SNYR Synergy CHC	$2.12M	N/A	0.00	5.81	N/A	N/A	-8.48%	12.75%	N/A

Latest GOVX, ESLA, BDRX, and SNYR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	GOVX GeoVax Labs	-$0.41	N/A	N/A	N/A	$0.37 million	N/A
5/15/2025	Q1 2025	SNYR Synergy CHC	$0.07	$0.10	+$0.03	$0.10	$9.03 million	$8.17 million
5/1/2025	Q1 2025	GOVX GeoVax Labs	-$0.59	-$0.45	+$0.14	-$0.45	$0.75 million	$1.64 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDRX Biodexa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	N/A
GOVX GeoVax Labs	N/A	N/A	N/A	N/A	N/A
SNYR Synergy CHC	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDRX Biodexa Pharmaceuticals	0.01	1.75	1.75
ESLA Estrella Immunopharma	N/A	0.22	0.22
GOVX GeoVax Labs	N/A	3.62	3.62
SNYR Synergy CHC	N/A	1.91	1.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDRX Biodexa Pharmaceuticals	17.51%
ESLA Estrella Immunopharma	0.35%
GOVX GeoVax Labs	6.09%
SNYR Synergy CHC	N/A

Insider Ownership

Company	Insider Ownership
BDRX Biodexa Pharmaceuticals	0.34%
ESLA Estrella Immunopharma	55.10%
GOVX GeoVax Labs	1.20%
SNYR Synergy CHC	56.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDRX Biodexa Pharmaceuticals	20	36.54 million	36.42 million	Not Optionable
ESLA Estrella Immunopharma	N/A	36.17 million	16.24 million	Not Optionable
GOVX GeoVax Labs	10	15.93 million	15.73 million	Not Optionable
SNYR Synergy CHC	40	9.19 million	3.99 million	N/A

GOVX, ESLA, BDRX, and SNYR Headlines

Recent News About These Companies

Synergy CHC Expands Retail Presence in North America

June 30, 2025 | tipranks.com

Synergy CHC Corp. (SNYR) Stock Price Today - WSJ

June 24, 2025 | wsj.com

Synergy CHC (NASDAQ: SNYR) Expands FOCUSfactor® to UAE & Turkey — Ignites Global Growth and New Revenue Streams

June 18, 2025 | finance.yahoo.com

Synergy CHC Corp. Expands International Licensing Deal with Gravity Pharma to Include Turkey, Securing $2 Million in Revenue

June 18, 2025 | quiverquant.comQ

Here is What You Need to Know Before Investing in Synergy CHC Corp. (SNYR)

June 18, 2025 | finance.yahoo.com

Here is What You Need to Know Before Investing in Synergy CHC Corp. (SNYR)

June 16, 2025 | insidermonkey.com

Synergy CHC Corp. (Uplisting) (NASDAQ:SNYR) CEO Jack Ross Buys 9,400 Shares

June 12, 2025 | insidertrades.com

New to The Street TV Spotlights Synergy CHC (NASDAQ:SNYR) as Former Coca-Cola Executive Joins to Drive FOCUSfactor(R) Energy Drink’s Global Expansion

June 11, 2025 | freep.comF

New to The Street TV Spotlights Synergy CHC (NASDAQ:SNYR) as Former Coca-Cola Executive Joins to Drive FOCUSfactor(R) Energy Drink's Global Expansion

June 10, 2025 | guardonline.comG

Synergy CHC Corp. Appoints Damian Marano as Vice President of Beverage to Accelerate Functional Beverage Expansion

June 10, 2025 | quiverquant.comQ

Synergy CHC (NASDAQ: SNYR) Taps Former Coca-Cola Executive to Help Drive FOCUSfactor Energy Drink Global Expansion

June 10, 2025 | globenewswire.com

Synergy CHC secures $20 million loan for growth and debt repayment

June 5, 2025 | investing.com

Synergy CHC Secures $20 Million Loan Agreement

June 4, 2025 | msn.com

Synergy CHC Announces New $20 Million Long-Term Credit Facility

June 4, 2025 | globenewswire.com

SNYR Synergy CHC Corp.

May 30, 2025 | seekingalpha.com

Synergy CHC Announces Appointment of Erik Shields as Vice President of Beverage

May 29, 2025 | finance.yahoo.com

Synergy CHC Corp. (Uplisting) (NASDAQ:SNYR) CEO Jack Ross Buys 5,000 Shares

May 22, 2025 | insidertrades.com

Analysts Offer Insights on Consumer Goods Companies: Wilmar International (OtherWLMIF) and Synergy CHC (SNYR)

May 21, 2025 | theglobeandmail.com

Synergy CHC Corp (SNYR) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges with ...

May 16, 2025 | uk.finance.yahoo.com

Synergy CHC Corp. Reports Strong Q1 2025 Earnings

May 15, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500
By Sam Quirke | June 30, 2025
View Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500
Rivian vs. Lucid: Who’s Best Positioned to Steal Tesla’s Thunder?
By Nathan Reiff | June 20, 2025
View Rivian vs. Lucid: Who’s Best Positioned to Steal Tesla’s Thunder?
Tesla Stock Could Accelerate on New EV Tax Legislation
By Gabriel Osorio-Mazilli | July 9, 2025
View Tesla Stock Could Accelerate on New EV Tax Legislation
Aeva & Mobileye: LiDAR Stocks Powering the Autonomous Revolution
By Dan Schmidt | July 2, 2025
View Aeva & Mobileye: LiDAR Stocks Powering the Autonomous Revolution
Tesla: 2 Plays Ahead of Next Week's Earnings Report
By Sam Quirke | July 15, 2025
View Tesla: 2 Plays Ahead of Next Week's Earnings Report

GOVX, ESLA, BDRX, and SNYR Company Descriptions

Biodexa Pharmaceuticals NASDAQ:BDRX

$0.84 -0.04 (-4.53%)

Closing price 03:59 PM Eastern

Extended Trading

$0.81 -0.03 (-3.81%)

As of 07:58 PM Eastern

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Estrella Immunopharma NASDAQ:ESLA

$0.84 -0.01 (-0.72%)

Closing price 04:00 PM Eastern

Extended Trading

$0.85 +0.01 (+0.62%)

As of 07:26 PM Eastern

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

GeoVax Labs NASDAQ:GOVX

$0.73 +0.04 (+6.43%)

As of 04:00 PM Eastern

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

Synergy CHC NASDAQ:SNYR

$3.43 +0.03 (+0.88%)

As of 03:59 PM Eastern

Synergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time